1. Real-life evidence about the use of intravenous brivaracetam in urgent seizures: The BRIV-IV study.
- Author
-
Villanueva, Vicente, Rodriguez-Osorio, Xiana, Juiz-Fernández, Álvaro, Sayas, Debora, Hampel, Kevin, Castillo, Ascensión, Montoya, Javier, Garcés, Mercedes, Campos, Dulce, Rubio-Nazábal, Eduardo, Fernández-Cabrera, Alejandro, Gifreu, Ariadna, Santamarina, Estevo, Hernández Pérez, Guillermo, Falip, Mercé, Parejo-Carbonell, Beatriz, García-Morales, Irene, Martínez, Ana Belen, Massot, Margarita, and Asensio, Montserrat
- Subjects
- *
EPILEPSY , *BOLUS drug administration , *SEIZURES (Medicine) , *STATUS epilepticus , *PEOPLE with epilepsy , *DIAGNOSIS of epilepsy - Abstract
• Intravenous brivaracetam for urgent seizures was effective and well-tolerated in our study. • 77.6% of patients responded to IV BRV, with a sustained response in 62.8% of them. • A high loading dose of 163.0 ± 73.0 mg was given and fast bolus infusion was related with a better response. • A prior use of IV LEV in the acute episode was related with a worse outcome. • An early use of IV BRV could be recommended although studies with larger series of patients are needed. Urgent seizures are a medical emergency for which new therapies are still needed. This study evaluated the use of intravenous brivaracetam (IV-BRV) in an emergency setting in clinical practice. BRIV-IV was a retrospective, multicenter, observational study. It included patients ≥18 years old who were diagnosed with urgent seizures (including status epilepticus (SE), acute repetitive seizures, and high-risk seizures) and who were treated with IV-BRV according to clinical practice in 14 hospital centers. Information was extracted from clinical charts and included in an electronic database. Primary effectiveness endpoints included the rate of IV-BRV responder patients, the rate of patients with a sustained response without seizure relapse in 12 h, and the time between IV-BRV administration and clinical response. Primary safety endpoints were comprised the percentage of patients with adverse events and those with adverse events leading to discontinuation. A total of 156 patients were included in this study. The mean age was 57.7 ± 21.5 years old with a prior diagnosis of epilepsy for 57.1% of patients. The most frequent etiologies were brain tumor-related (18.1%) and vascular (11.2%) epilepsy. SE was diagnosed in 55.3% of patients. The median time from urgent seizure onset to IV treatment administration was 60.0 min (range: 15.0–360.0), and the median time from IV treatment to IV-BRV was 90.0 min (range: 30.0–2400.0). Regarding dosage, the mean bolus infusion was 163.0 ± 73.0 mg and the mean daily dosage was 195.0 ± 87.0 mg. A total of 77.6% of patients responded to IV-BRV (66.3% with SE vs. 91% other urgent seizures) with a median response time of 30.0 min (range: 10.0–60.0). A sustained response was achieved in 62.8% of patients. However, adverse events were reported in 14.7%, which were predominantly somnolence and fatigue, with 4.5% leading to discontinuation. Eighty-six percent of patients were discharged with oral brivaracetam. IV-BRV in emergency settings was effective, and tolerability was good for most patients. However, a larger series is needed to confirm the outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF